Ex vivo rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice
- 15 April 2011
- journal article
- Published by Elsevier BV in Blood Cells, Molecules, and Diseases
- Vol. 46 (4), 318-320
- https://doi.org/10.1016/j.bcmd.2011.02.006
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in miceJCI Insight, 2010
- Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in miceBlood, 2010
- Overexpression of Rheb2 enhances mouse hematopoietic progenitor cell growth while impairing stem cell repopulationBlood, 2009
- TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen speciesThe Journal of Experimental Medicine, 2008
- Identification of parameters required for efficient lentiviral vector transduction and engraftment of human cord blood CD34+ NOD/SCID-repopulating cellsExperimental Hematology, 2008
- Mammalian Target of Rapamycin Is Required for Thrombopoietin-Induced Proliferation of Megakaryocyte ProgenitorsThe International Journal of Cell Cloning, 2006
- Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cellsLeukemia, 2005
- Analysis of mTOR signaling by the small G‐proteins, Rheb and RhebL1FEBS Letters, 2005
- Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell supportLeukemia, 2004
- Hematopoietic Reconstitution in a Patient with Fanconi's Anemia by Means of Umbilical-Cord Blood from an HLA-Identical SiblingThe New England Journal of Medicine, 1989